AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. has filed an S-1 to register up to 31,287,933 shares of common stock for resale by existing holders of Class H and Class I warrants and related placement agent warrants. AIM will not receive proceeds from these stockholder sales, though full cash exercise of the warrants could bring in about $14.5 million for general corporate purposes and working capital.
The filing highlights substantial potential dilution, as common shares could rise from 24,328,623 to 55,616,556 if all registered warrants are exercised. AIM describes its focus on developing Ampligen for late-stage pancreatic cancer and other oncology and antiviral indications, while also warning about NYSE American listing risks, possible penny stock status, and significant stock price volatility.
AIM ImmunoTech Inc. filed an update describing new investor-focused materials on its lead drug candidate Ampligen for Ebola virus disease preparedness. The company released a Virtual Investor “What This Means” video segment and an Ebola-focused investor presentation reviewing previously published preclinical data and regulatory groundwork.
Management discusses the ongoing Bundibugyo Ebola outbreak, the lack of approved targeted therapies or vaccines for this strain, and Ampligen’s immune‑modulating mechanism as a PAMP‑restricted TLR3 agonist. The materials highlight Biosafety Level 4 preclinical findings showing 100% survival with early Ampligen administration in a lethal Ebola mouse model and note orphan drug designations from U.S. and European regulators, while emphasizing that significant additional testing and human trials are still required.
AIM ImmunoTech Inc. ownership disclosure: three related reporting persons (Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC) filed a joint Schedule 13G describing potential beneficial ownership tied to a Securities Purchase Agreement executed May 20, 2026.
The filing states that 1,538,462 shares of Common Stock may be issuable to Intracoastal at closing, representing approximately 8.5% based on 16,505,501 shares outstanding as of May 20, 2026. It also discloses an Intracoastal Warrant for 3,076,924 shares subject to stockholder approval and a 4.99% exercise blocker. As of close of business on May 27, 2026, the filing reports the reporting persons may be deemed to beneficially own 0 shares.
AIM ImmunoTech Inc. entered into agreements for a registered direct stock offering and a concurrent private placement of warrants. The company is selling 7,519,351 shares of common stock at $0.325 per share, for expected gross proceeds of approximately $2.4 million before expenses.
The concurrent private placement includes Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share, potentially adding about $4.9 million in gross proceeds if fully exercised for cash. AIM expects to have at least $6.0 million in stockholders' equity upon closing.
Ladenburg Thalmann is acting as placement agent, receiving an 8.0% cash fee, a 0.75% management fee on aggregate gross proceeds, reimbursement of expenses, and 451,161 Placement Agent Warrants with a $0.40625 exercise price. The offerings are expected to close on or about May 21, 2026, subject to customary conditions.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.
The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.
AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.
Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.
The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.
AIM ImmunoTech Inc. filed a report highlighting a Virtual Investor Key Opinion Leader segment focused on Ampligen (rintatolimod) for late-stage pancreatic cancer. The segment features Professor Casper H.J. van Eijck of Erasmus Medical Center and AIM’s CEO discussing Ampligen’s mechanism, clinical data and development strategy.
The company recaps prior Named Patient Program results suggesting longer progression-free survival and overall survival versus historical controls, and notes ongoing Phase 2 DURIPANC trial work with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The press release and video segment are furnished, not filed, and include customary forward-looking statement cautions.
AIM ImmunoTech Inc. Schedule 13G shows Orca Capital beneficially owns 1,793,999 shares of common stock, representing 9.9% of the class immediately after the issuer's warrant inducement transaction.
The filing states the ownership calculation is based on 17,369,915 shares outstanding after the inducement and excludes 1,333,131 shares issuable upon exercise of common warrants, which are subject to the verbatim "9.99% Blocker".